TR200101498T2 - İkameli benzimidazoller ve parp inhibitörleri olarak kullanımları - Google Patents

İkameli benzimidazoller ve parp inhibitörleri olarak kullanımları

Info

Publication number
TR200101498T2
TR200101498T2 TR2001/01498T TR200101498T TR200101498T2 TR 200101498 T2 TR200101498 T2 TR 200101498T2 TR 2001/01498 T TR2001/01498 T TR 2001/01498T TR 200101498 T TR200101498 T TR 200101498T TR 200101498 T2 TR200101498 T2 TR 200101498T2
Authority
TR
Turkey
Prior art keywords
relates
compounds
parp inhibitors
substituted benzimidazoles
parp
Prior art date
Application number
TR2001/01498T
Other languages
English (en)
Inventor
Lubisch Wilfried
Kock Michael
H�Ger Thomas
Schult Sabine
Grandel Roland
M�Ller Reinhold
Original Assignee
Basf Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1999116460 external-priority patent/DE19916460B4/de
Application filed by Basf Aktiengesellschaft filed Critical Basf Aktiengesellschaft
Publication of TR200101498T2 publication Critical patent/TR200101498T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Bulus, R1 ve R4 'ün hidrojen veya tanimli ikame ediciler, A'nin bir veya iki nitrojen atomuna ihtiva etmesine ilaveten bir oksijen veya sülfür atomunun da bulunabildigi 4 ila 8 üyeli doymus veya monoetanoid heterosiklik bir halka oldugu genek formül (1a) veya (1b)'ye ait bilesiklerle ilgilidir. Bulus, bunlarin tatomer formlariyla, muhtemel enantiyomer ve diyasteromer formlariyla, bunlarin ön ilaçlariyla ve ayni zamanda muhtemel fizyolojik açidan kabul gören tuzlariyla da ilgilidir. Bulus, adi geçen bilesiklerin, PARP'nin patolojik açidan artan aktivitesine bagli hastaliklarin tedavisi içinkullanilmasiyla ilgilidir.(Sekil 1a ve 1b)
TR2001/01498T 1998-11-27 1999-11-23 İkameli benzimidazoller ve parp inhibitörleri olarak kullanımları TR200101498T2 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19854933 1998-11-27
DE1999116460 DE19916460B4 (de) 1999-04-12 1999-04-12 Substituierte Benzimidazole, deren Herstellung und Anwendung

Publications (1)

Publication Number Publication Date
TR200101498T2 true TR200101498T2 (tr) 2001-11-21

Family

ID=26050434

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/01498T TR200101498T2 (tr) 1998-11-27 1999-11-23 İkameli benzimidazoller ve parp inhibitörleri olarak kullanımları

Country Status (32)

Country Link
US (2) US6448271B1 (tr)
EP (1) EP1133477B1 (tr)
JP (1) JP3432800B2 (tr)
KR (1) KR100417779B1 (tr)
CN (1) CN1184208C (tr)
AR (1) AR021400A1 (tr)
AT (1) ATE259789T1 (tr)
AU (1) AU764216B2 (tr)
BG (1) BG65047B1 (tr)
BR (1) BR9915701A (tr)
CA (1) CA2352554C (tr)
CZ (1) CZ300148B6 (tr)
DE (1) DE59908600D1 (tr)
DK (1) DK1133477T3 (tr)
ES (1) ES2216625T3 (tr)
HK (1) HK1042084B (tr)
HR (1) HRP20010484B1 (tr)
HU (1) HUP0200749A3 (tr)
IL (2) IL143303A0 (tr)
MY (1) MY128488A (tr)
NO (1) NO20012570L (tr)
NZ (1) NZ511825A (tr)
PL (1) PL196367B1 (tr)
PT (1) PT1133477E (tr)
RU (1) RU2001117757A (tr)
SI (1) SI1133477T1 (tr)
SK (1) SK285529B6 (tr)
TR (1) TR200101498T2 (tr)
TW (1) TWI247741B (tr)
UA (1) UA61158C2 (tr)
WO (1) WO2000032579A1 (tr)
ZA (1) ZA200104118B (tr)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291425B1 (en) 1999-09-01 2001-09-18 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage
DE59911249D1 (de) 1998-11-03 2005-01-13 Abbott Gmbh & Co Kg Substituierte 2-phenylbenzimidazole, deren herstellung und anwendung
DE19920936A1 (de) * 1999-05-07 2000-11-09 Basf Ag Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung
WO2001021615A1 (fr) * 1999-09-17 2001-03-29 Yamanouchi Pharmaceutical Co., Ltd. Dérivés de benzimidazole
EP1309594B1 (fr) * 2000-08-08 2004-12-15 Sanofi-Aventis Derives de benzimidazole, leur preparation et leur application en therapeutique
FR2812878B1 (fr) * 2000-08-08 2002-10-11 Sanofi Synthelabo Derives de benzimidazole, leur preparation et leur application en therapeutique
FR2816941B1 (fr) * 2000-11-23 2003-01-31 Sanofi Synthelabo Derives de benzimidazole, leur preparation et leur application en therapeutique
FR2816942B1 (fr) * 2000-11-23 2003-05-09 Sanofi Synthelabo Derives de benzimidazole, leur preparation et leur application en therapeutique
JPWO2002068407A1 (ja) * 2001-02-28 2004-06-24 山之内製薬株式会社 ベンゾイミダゾール化合物
BR0208010A (pt) 2001-03-12 2004-12-21 Avanir Pharmaceuticals Composto de benzimidazol para modulação de ige e inibição de proliferação celular
US20040242635A1 (en) * 2001-03-30 2004-12-02 Painter Rachel J. Encapsulated dyes in cosmetic compositions
WO2003007959A1 (en) * 2001-07-16 2003-01-30 Fujisawa Pharmaceutical Co., Ltd. Quinoxaline derivatives which have parp inhibitory action
ATE405658T1 (de) 2002-07-26 2008-09-15 Basf Plant Science Gmbh Neue selektionsverfahren
JPWO2004014873A1 (ja) * 2002-08-09 2005-12-02 杏林製薬株式会社 ４−置換キナゾリン−８−カルボン酸アミド誘導体とその薬理上許容される付加塩
TWI276631B (en) 2002-09-12 2007-03-21 Avanir Pharmaceuticals Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
AU2003270426A1 (en) 2002-09-12 2004-04-30 Avanir Pharmaceuticals PHENYL-INDOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION
EP1551811A1 (en) * 2002-10-17 2005-07-13 Amgen Inc. Benzimidazole derivatives and their use as vanilloid receptor ligands
HU0301154D0 (en) * 2003-04-28 2003-07-28 Hideg Kalman Dr Pharmaceutical composition
CN101137752B (zh) 2005-03-08 2013-04-03 巴斯福植物科学有限公司 增强表达的内含子序列
ES2400287T3 (es) * 2005-03-14 2013-04-08 High Point Pharmaceuticals, Llc Derivados de benzazol, composiciones y procedimientos de uso como inhibidores de beta-secretasa
TWI375673B (en) * 2005-04-11 2012-11-01 Abbott Lab 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
AU2012200399B2 (en) * 2005-04-11 2013-07-11 Abbvie Ireland Unlimited Company 1H-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors
US7728026B2 (en) 2005-04-11 2010-06-01 Abbott Laboratories, Inc. 2-substituted-1 h-benzimidazile-4-carboxamides are PARP inhibitors
CA2612979A1 (en) * 2005-06-10 2006-12-21 Bipar Sciences, Inc. Parp modulators and treatment of cancer
US7825543B2 (en) 2005-07-12 2010-11-02 Massachusetts Institute Of Technology Wireless energy transfer
CN102983639B (zh) 2005-07-12 2016-01-27 麻省理工学院 无线非辐射能量传递
CA2615374A1 (en) * 2005-07-18 2007-01-25 Ernest Kun Kun Treatment of cancer
EP1957477B1 (en) 2005-09-29 2011-12-07 Abbott Laboratories 1h-benzimidazole-4-carboxamides substituted with phenyl at the 2-position are potent parp inhibitors
EP1779849A1 (en) * 2005-10-28 2007-05-02 Nikem Research S.R.L. V-ATPase inhibitors for the treatment of septic shock
WO2007059230A2 (en) 2005-11-15 2007-05-24 Abbott Laboratories Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors
ME02121B (me) * 2006-01-17 2014-06-30 Abbvie Ireland Unlimited Co Kombinovana terapija sa parp inhibitorima
US20080280867A1 (en) * 2006-01-17 2008-11-13 Abbott Laboratories Combination therapy with parp inhibitors
US20080293795A1 (en) * 2006-01-17 2008-11-27 Abbott Laboratories Combination therapy with parp inhibitors
US20080146638A1 (en) * 2006-01-17 2008-06-19 Abbott Laboratories Combination therapy with parp inhibitors
US20090029966A1 (en) * 2006-01-17 2009-01-29 Abbott Laboratories Combination therapy with parp inhibitors
EP2007733B1 (en) * 2006-04-03 2016-05-25 MSD Italia S.r.l. Amide substituted indazole and benzotriazole derivatives as poly(adp-ribose)polymerase (parp) inhibitors
CA2647373C (en) * 2006-05-02 2014-03-18 Abbott Laboratories Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors
US20100279327A1 (en) * 2006-06-12 2010-11-04 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
WO2008147418A1 (en) * 2006-06-12 2008-12-04 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
US20080262062A1 (en) * 2006-11-20 2008-10-23 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
CA2662337A1 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Inhibition of fatty acid synthesis by parp inhibitors and methods of treatment thereof
JP2010502730A (ja) * 2006-09-05 2010-01-28 バイパー サイエンシズ，インコーポレイティド 癌の治療法
AR064777A1 (es) * 2007-01-10 2009-04-22 Inst Di Reserche D Biolog Mole Indazoles sustituidos con amida como inhibidores de poli (adp- ribosa) polimerasa (parp)
EP2155195B1 (en) * 2007-04-13 2014-07-16 Millennium Pharmaceuticals, Inc. Combination anticoagulant therapy with a compound that acts as a factor Xa inhibitor
US8067613B2 (en) * 2007-07-16 2011-11-29 Abbott Laboratories Benzimidazole poly(ADP ribose)polymerase inhibitors
US8138168B1 (en) * 2007-09-26 2012-03-20 Takeda Pharmaceutical Company Limited Renin inhibitors
CA2696423A1 (en) * 2007-10-12 2009-04-16 Guidong Zhu 2-((r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide crystalline form 2
CN103169973A (zh) * 2007-11-12 2013-06-26 彼帕科学公司 使用4-碘-3-硝基苯甲酰胺化合物与抗肿瘤剂组合治疗乳腺癌
KR20100102607A (ko) * 2007-11-12 2010-09-24 바이파 사이언스 인코포레이티드 Ｐａｒｐ 억제제를 단독으로 사용하거나 항종양제와 병용하여 자궁암 및 난소암을 치료하는 방법
JP5989965B2 (ja) 2008-01-08 2016-09-07 メルク シャープ エンド ドーム リミテッド ２−｛４−［（３ｓ）−ピペリジン−３−イル］フェニル｝−２ｈ−インダゾール−７−カルボキサミドの薬学的に許容される塩
CA2713156A1 (en) * 2008-02-04 2009-08-13 Bipar Sciences, Inc. Methods of diagnosing and treating parp-mediated diseases
WO2009099736A2 (en) * 2008-02-06 2009-08-13 Lead Therapeutics, Inc. Benzoxazole carboxamide inhibitors of poly(adp-ribose)polymerase (parp)
WO2010083199A1 (en) * 2009-01-19 2010-07-22 Abbott Laboratories Benzthiazole inhibitors of poly(adp-ribose)polymerase
WO2011002520A2 (en) 2009-07-02 2011-01-06 Angion Biomedica Corp. Small molecule inhibitors of parp activity
EP2504439B1 (en) 2009-11-27 2016-03-02 BASF Plant Science Company GmbH Optimized endonucleases and uses thereof
WO2011064751A1 (en) 2009-11-27 2011-06-03 Basf Plant Science Company Gmbh Chimeric endonucleases and uses thereof
US10316304B2 (en) 2009-11-27 2019-06-11 Basf Plant Science Company Gmbh Chimeric endonucleases and uses thereof
WO2011107504A1 (de) 2010-03-04 2011-09-09 Bayer Cropscience Ag Fluoralkyl- substituierte 2 -amidobenzimidazole und deren verwendung zur steigerung der stresstoleranz in pflanzen
US20140051737A1 (en) * 2011-05-10 2014-02-20 Universite Laval Methods for the treatment and diagnostic of pulmonary arterial hypertension
WO2013014038A1 (en) * 2011-07-26 2013-01-31 Nerviano Medical Sciences S.R.L. 3-oxo-2,3-dihydro-1h-indazole-4-carboxamide derivatives as parp-1 inhibitors
EP2561759A1 (en) 2011-08-26 2013-02-27 Bayer Cropscience AG Fluoroalkyl-substituted 2-amidobenzimidazoles and their effect on plant growth
CN103130723B (zh) 2011-11-30 2015-01-14 成都地奥制药集团有限公司 一种多聚(adp-核糖)聚合酶抑制剂
CN102617502A (zh) * 2012-03-19 2012-08-01 江苏先声药物研究有限公司 一类苯并噁唑衍生物及其医药应用
EA201590482A1 (ru) * 2012-09-05 2015-07-30 Байер Кропсайенс Аг Применение замещенных 2-амидобензимидазолов, 2-амидобензоксазолов и 2-амидобензотиазолов или их солей в качестве биологически активных веществ против абиотического стресса растений
GB201223265D0 (en) * 2012-12-21 2013-02-06 Selvita Sa Novel benzimidazole derivatives as kinase inhibitors
CN104230897B (zh) * 2013-06-17 2016-07-06 上海汇伦生命科技有限公司 苯并咪唑-2-哌嗪杂环类化合物、其药物组合物及其制备方法和用途
CN104230898B (zh) * 2013-06-17 2016-06-29 上海汇伦生命科技有限公司 苯并咪唑-2-哌嗪杂环类化合物、其药物组合物及其制备方法和用途
CN103396405A (zh) * 2013-08-21 2013-11-20 中国药科大学 具有parp抑制作用的苯并咪唑-4-甲酰胺衍生物
CN103483322A (zh) * 2013-08-21 2014-01-01 中国药科大学 5-氟-1h-苯并咪唑-4-甲酰胺衍生物、其制法及医药用途
US10874641B2 (en) 2016-07-28 2020-12-29 Mitobridge, Inc. Methods of treating acute kidney injury
ES2973850T3 (es) 2016-09-20 2024-06-24 Centre Leon Berard Derivados del benzoimidazol como agentes anticancerígenos
AU2017355402A1 (en) 2016-11-02 2019-05-30 Health Research, Inc. Combination treatment with antibody-drug conjugates and PARP inhibitors
CN109232540A (zh) * 2018-06-15 2019-01-18 深圳市坤健创新药物研究院 一种取代苯并咪唑衍生物及应用
CN108997320A (zh) * 2018-08-30 2018-12-14 深圳市坤健创新药物研究院 一种含氟取代苯并咪唑衍生物及应用
US20210347758A1 (en) 2018-10-03 2021-11-11 Tesaro, Inc. Crystalline Forms of Niraparib Freebase

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1354554U (tr)
US4093726A (en) * 1976-12-02 1978-06-06 Abbott Laboratories N-(2-benzimidazolyl)-piperazines
IL123147A (en) * 1995-08-02 2004-02-19 Univ Newcastle Ventures Ltd Benzamide imidazole - 4 carboxamide and their use
US6001866A (en) 1995-10-05 1999-12-14 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
US5972980A (en) 1995-10-05 1999-10-26 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
WO1997012613A1 (en) 1995-10-05 1997-04-10 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
US5830905A (en) 1996-03-29 1998-11-03 Viropharma Incorporated Compounds, compositions and methods for treatment of hepatitis C
ES2124167B1 (es) 1996-06-04 1999-09-16 Espanola Prod Quimicos Nuevos derivados del bencimidazol con actividad antihistaminica.
GB9702701D0 (en) 1997-02-01 1997-04-02 Univ Newcastle Ventures Ltd Quinazolinone compounds
US6303627B1 (en) 1998-06-19 2001-10-16 Eli Lilly And Company Inhibitors of serotonin reuptake

Also Published As

Publication number Publication date
NO20012570D0 (no) 2001-05-25
UA61158C2 (uk) 2003-11-17
NZ511825A (en) 2003-08-29
EP1133477B1 (de) 2004-02-18
RU2001117757A (ru) 2004-02-27
HK1042084B (zh) 2005-09-02
PL196367B1 (pl) 2007-12-31
KR20010080596A (ko) 2001-08-22
ES2216625T3 (es) 2004-10-16
SK285529B6 (sk) 2007-03-01
ATE259789T1 (de) 2004-03-15
IL143303A (en) 2006-12-10
CA2352554C (en) 2006-10-10
PL347884A1 (en) 2002-04-22
KR100417779B1 (ko) 2004-02-05
HRP20010484A2 (en) 2003-04-30
US6448271B1 (en) 2002-09-10
DK1133477T3 (da) 2004-06-21
IL143303A0 (en) 2002-04-21
AU3034300A (en) 2000-06-19
BR9915701A (pt) 2001-08-14
HUP0200749A3 (en) 2003-03-28
HRP20010484B1 (hr) 2010-08-31
SI1133477T1 (en) 2004-06-30
SK7142001A3 (en) 2001-12-03
WO2000032579A1 (de) 2000-06-08
CA2352554A1 (en) 2000-06-08
ZA200104118B (en) 2002-05-21
USRE39608E1 (en) 2007-05-01
HK1042084A1 (en) 2002-08-02
PT1133477E (pt) 2004-06-30
DE59908600D1 (de) 2004-03-25
NO20012570L (no) 2001-07-13
JP2002531442A (ja) 2002-09-24
CN1332731A (zh) 2002-01-23
HUP0200749A2 (en) 2002-08-28
EP1133477A1 (de) 2001-09-19
BG65047B1 (bg) 2007-01-31
AU764216B2 (en) 2003-08-14
JP3432800B2 (ja) 2003-08-04
CZ300148B6 (cs) 2009-02-25
CZ20011855A3 (cs) 2001-08-15
BG105596A (en) 2002-02-28
CN1184208C (zh) 2005-01-12
AR021400A1 (es) 2002-07-17
MY128488A (en) 2007-02-28
TWI247741B (en) 2006-01-21

Similar Documents

Publication Publication Date Title
TR200101498T2 (tr) İkameli benzimidazoller ve parp inhibitörleri olarak kullanımları
GT199900139A (es) Derivados de quinolin-2-ona ùtiles como agentes contra el càncer.
DE60015927D1 (en) Phenylharnstoff und phenylthioharnstoffderivate
MY117896A (en) Quinazoline derivatives
PT870768E (pt) Derivados azaindole-etilamina como agentes de ligacao nicotinicos aos receptores de acetilcolina
MY135841A (en) Novel benzodioxoles
BG105271A (bg) Производни на 1h-имидазопиридин
TR200000837A2 (tr) Anti-kanser bileşimleri hazırlamak için işlem ve ara maddeler.
MY119542A (en) Therapeutic biaryl derivatives
DE60107435D1 (de) 2-adamantylethylamine und deren verwendung bei der behandlung von abnormalitäten in der glutamat transmission
TR200102789T2 (tr) Cns bozukluklarının tedavisi için 1-Arensülfonil-2-aril-pirolidin ve piperidin türevleri
DE69808099D1 (de) Substituierte 6-alkylphenanthridine
NZ334701A (en) Dihydropyrones and use in treating retrovirus infections and diseases
DE69919349D1 (de) Piperidinyl- und n-amidinopiperidinyl-derivate
NZ337749A (en) Benzimidazole derivative and their use in allergy-related disease
TR199900153T2 (tr) Hücre çogalmasini önlemek için ikame edilmis bisindolilmaleimitler.
DE60009263D1 (de) 2-adamantanmethanamin verbindungen zur behandlung von abweichungen bei glutamatergischen übertragungen
ATE247903T1 (de) Fungizide zusammensetzung enthaltend ein n- benzoyl-n'-phenyl-harnstoff derivat
ES2161892T3 (es) Derivados de indol como profarmacos de agonistas de los receptores afines a 5-ht1.
DK0784973T3 (da) Quinoxalinderivater til behandling af tinnitus
EP1431293A4 (en) WATER-SOLUBLE PHENYLPYRIDAZINE DERIVATIVES AND MEDICINAL PRODUCTS CONTAINING THEM
ATE64095T1 (de) Verwendung von imidazochinazolinen zur behandlung und verhinderung von nephritis.
PT923576E (pt) Derivados de 4-amino-etoxi-indolona como agonistas de dopamina d2
ID26809A (id) Senyawa-senyawa turunan sianoiminokuinoksalin
BR0110328A (pt) Compostos heterocìclicos com atividade antiinflamatória